CYP2C19 and CYP3A4 activity and ADP-induced platelet reactivity in prasugrel- or ticagrelor-treated STEMI patients: monocentric study in PRAGUE-18 trial participants

References

• Brandt JT, Close SL, Iturria SJ, et al. (2007). Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 5:2429–36.
   PubMed Web of Science ®Google Scholar
• Cuisset T, Loosveld M, Morange PE, et al. (2012). CYP2C19*2 and *17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome. JACC Cardiovasc Interv 5:1280–7.
   PubMed Web of Science ®Google Scholar
• Dayoub EJ, Seigerman M, Tuteja S, et al. (2018). Trends in platelet adenosine diphosphate P2Y12 receptor inhibitor use and adherence among antiplatelet-naive patients after percutaneous coronary intervention, 2008–2016. JAMA Intern Med 178:943.
   PubMed Web of Science ®Google Scholar
• Djebli N, Fabre D, Boulenc X, et al. (2015). Physiologically based pharmacokinetic modeling for sequential metabolism: effect of CYP2C19 genetic polymorphism on clopidogrel and clopidogrel active metabolite pharmacokinetics. Drug Metab Dispos 43:510–22.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. (2019). Drug development and drug interactions: table of substrates, inhibitors and inducers. Available from http://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers [last accessed 12 Mar 2019].
   Google Scholar
• Ford NF. (2016). The metabolism of clopidogrel: CYP2C19 is a minor pathway. J Clin Pharmacol 56:1474–83.
   PubMed Web of Science ®Google Scholar
• Franken CC, Kaiser AFC, Krüger JC, et al. (2013). Cytochrome P450 2B6 and 2C9 genotype polymorphism – a possible cause of prasugrel low responsiveness. Thromb Haemost 110:131–40.
   PubMed Web of Science ®Google Scholar
• Fricke-Galindo I, Céspedes-Garro C, Rodrigues-Soares F, et al. (2016). Interethnic variation of CYP2C19 alleles, ‘predicted’ phenotypes and ‘measured’ metabolic phenotypes across world populations. Pharmacogenomics J 16:113–23.
   PubMed Web of Science ®Google Scholar
• Grosdidier C, Quilici J, Loosveld M, et al. (2013). Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications. Am J Cardiol 111:985–90.
   PubMed Web of Science ®Google Scholar
• Gumus E, Karaca O, Babaoglu MO, et al. (2012). Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype–phenotype correlation in childhood. Eur J Clin Pharmacol 68:629–36.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Shuldiner AR, Bliden KP, et al. (2011). The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. Am Heart J 161:598–604.
   PubMed Web of Science ®Google Scholar
• Hagihara K, Kazui M, Ikenaga H, et al. (2011). The intestine as an important contributor to prasugrel active metabolite formation in vivo. Drug Metab Dispos 39:565–70.
   PubMed Web of Science ®Google Scholar
• Holmberg MT, Tornio A, Hyvärinen H, et al. (2015). Effect of grapefruit juice on the bioactivation of prasugrel. Br J Clin Pharmacol 80:139–45.
   PubMed Web of Science ®Google Scholar
• Holmberg MT, Tornio A, Joutsi-Korhonen L, et al. (2013). Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjects. Br J Clin Pharmacol 75:1488–96.
   PubMed Web of Science ®Google Scholar
• Kazui M, Nishiya Y, Ishizuka T, et al. (2010). Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 38:92–9.
   PubMed Web of Science ®Google Scholar
• Kim K-A, Kim M-J, Park J-Y, et al. (2003). Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes. Drug Metab Dispos 31:1227–34.
   PubMed Web of Science ®Google Scholar
• Kostolanská K, Peš O, Zendulka O, et al. (2019). Determination of lansoprazole, 5-hydroxylansoprazole, and lansoprazole sulfone in human plasma for CYP2C19 and CYP3A4 phenotyping. Chem Pap 73:2955–63.
   Web of Science ®Google Scholar
• Li Y, Zhang W, Guo D, et al. (2008). Pharmacokinetics of the new proton pump inhibitor ilaprazole in Chinese healthy subjects in relation to CYP3A5 and CYP2C19 genotypes. Clin Chim Acta 391:60–7.
   PubMed Web of Science ®Google Scholar
• Machal J, Hlinomaz O. (2019). Efficacy of P2Y12 receptor blockers after myocardial infarction and genetic variability of their metabolic pathways. Curr Vasc Pharmacol 17:35–40.
   PubMed Web of Science ®Google Scholar
• McDonald MG, Au NT, Rettie AE. (2015). P450-based drug-drug interactions of amiodarone and its metabolites: diversity of inhibitory mechanisms. Drug Metab Dispos 43:1661–9.
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, et al. (2009). Cytochrome P450 genetic polymorphisms and the response to prasugrel relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119:2553–60.
   PubMed Web of Science ®Google Scholar
• Miniscalco A, Lundahl J, Regårdh CG, et al. (1992). Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. J Pharmacol Exp Ther 261:1195–9.
   PubMed Web of Science ®Google Scholar
• Motovska Z, Hlinomaz O, Miklik R, et al. (2016). Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: multicenter randomized PRAGUE-18 study. Circulation 134:1603–12.
   PubMed Web of Science ®Google Scholar
• Naritomi Y, Terashita S, Kagayama A. (2004). Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate. Xenobiotica 34:415–27.
   PubMed Web of Science ®Google Scholar
• Ohyama K, Nakajima M, Suzuki M, et al. (2001). Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. Br J Clin Pharmacol 49:244–53.
   Web of Science ®Google Scholar
• Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A. (1996). Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther 277:805–16.
   PubMed Web of Science ®Google Scholar
• Pharmacogene Variation Consortium (PharmVar). 2018. CYP2C19 allele nomenclature. Available from: http://www.pharmvar.org/htdocs/archive/index_original.htm [last accessed 27 Feb 2020].
   Google Scholar
• Rehmel JLF, Eckstein JA, Farid NA, et al. (2006). Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 34:600–7.
   PubMed Web of Science ®Google Scholar
• Roche Ltd. (2018). Multiplate® ADPtest [online]. Available from: http://www.cobas.com/home/product/hemostasis-testing/multiplate-analyzer.html [last accessed 18 Apr 2018].
   Google Scholar
• Sabouret P, Taiel-Sartral M. (2014). New antiplatelet agents in the treatment of acute coronary syndromes. Arch Cardiovasc Dis 107:178–87.
   PubMed Web of Science ®Google Scholar
• Saito M, Yasui-Furukori N, Uno T, et al. (2005). Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. Br J Clin Pharmacol 59:302–9.
   PubMed Web of Science ®Google Scholar
• Savi P, Pereillo JM, Uzabiaga MF, et al. (2000). Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 84:891–6.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Uno T, Niioka T, et al. (2006). Sensitive determination of omeprazole and its two main metabolites in human plasma by column-switching high-performance liquid chromatography: application to pharmacokinetic study in relation to CYP2C19 genotypes. J Chromatogr B Analyt Technol Biomed Life Sci 832:241–8.
   PubMed Web of Science ®Google Scholar
• Shu Y, Wang LS, Xiao WM, et al. (2000). Probing CYP2C19 and CYP3A4 activities in Chinese liver microsomes by quantification of 5-hydroxyomeprazole and omeprazole sulphone. Acta Pharmacol Sin 21:753–8.
   PubMed Web of Science ®Google Scholar
• Tang M, Mukundan M, Yang J, et al. (2006). Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther 319:1467–76.
   PubMed Web of Science ®Google Scholar
• Taubert D, von Beckerath N, Grimberg G, et al. (2006). Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 80:486–501.
   PubMed Web of Science ®Google Scholar
• Teng R, Butler K. (2013). A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers. Eur J Clin Pharmacol 69:1801–8.
   PubMed Web of Science ®Google Scholar
• Teng R, Oliver S, Hayes MA, Butler K. (2010). Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos 38:1514–21.
   PubMed Web of Science ®Google Scholar
• Thelen K, Dressman JB. (2009). Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol 61:541–58.
   PubMed Web of Science ®Google Scholar
• Uno T, Yasui-Furukori N, Takahata T, et al. (2005). Determination of lansoprazole and two of its metabolites by liquid–liquid extraction and automated column-switching high-performance liquid chromatography: application to measuring CYP2C19 activity. J Chromatogr B 816:309–14.
   PubMed Web of Science ®Google Scholar
• Varenhorst C, James S, Erlinge D, et al. (2009). Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J 30:1744–52.
   PubMed Web of Science ®Google Scholar
• Vidali M, Rolla R, Parrella M, et al. (2012). Role of the laboratory in monitoring patients receiving dual antiplatelet therapy. Int J Lab Hematol 34:484–94.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. (2009). Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–57.
   PubMed Web of Science ®Google Scholar
• Werk AN, Cascorbi I. (2014). Functional gene variants of CYP3A4. Clin Pharmacol Ther 96:340–8.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. (2007). Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001–15.
   PubMed Web of Science ®Google Scholar
• Yanagida Y, Watanabe M, Takeba Y, et al. (2009). Potential of lansoprazole as a novel probe for cytochrome P450 3A activity by measuring lansoprazole sulfone in human liver microsomes. Biol Pharm Bull 32:1422–6.
   PubMed Web of Science ®Google Scholar
• Zahno A, Brecht K, Bodmer M, et al. (2010). Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro. Br J Pharmacol 161:393–404.
   PubMed Web of Science ®Google Scholar
• Zanger UM, Schwab M. (2013). Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103–41.
   PubMed Web of Science ®Google Scholar
• Zeymer U, Widimsky P, Danchin N, et al. (2016). P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries. Eur Heart J Cardiovasc Pharmacother 2:229–43.
   PubMed Web of Science ®Google Scholar
• Zhou D, Andersson TB, Grimm SW. (2011a). In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics. Drug Metab Dispos 39:703–10.
   PubMed Web of Science ®Google Scholar
• Zhou D, Andersson TB, Grimm SW. (2011b). In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics. Drug Metab Dispos 39:703–10.
   PubMed Web of Science ®Google Scholar
• Zhou S-F. (2008). Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 9:310–22.
   PubMed Web of Science ®Google Scholar